Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – What’s Next?

Pharming Group (NASDAQ:PHAR) shares saw unusually-strong trading volume on Friday . Approximately 3,008 shares changed hands during trading, a decline of 41% from the previous session’s volume of 5,088 shares.The stock last traded at $7.78 and had previously closed at $7.56.

Analyst Ratings Changes

Several research analysts have recently weighed in on PHAR shares. Oppenheimer cut their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday, October 24th.

Pharming Group Stock Performance

The stock has a market cap of $523.65 million, a PE ratio of -29.69 and a beta of 0.05. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The stock has a 50-day simple moving average of $8.21 and a 200-day simple moving average of $8.15.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.